{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:04Z","timestamp":1790957584978,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais, grant numbers","award":["BPD-01010-22, APQ-03221-18, APQ02281-18, APQ02618-23 and RED-00202-22"],"award-info":[{"award-number":["BPD-01010-22, APQ-03221-18, APQ02281-18, APQ02618-23 and RED-00202-22"]}]},{"name":"FINEP - Financiadora de Estudos e Projetos under MCTI\/FINEP \u2013 MS\/SCTIE\/DGITIS\/CGITS","award":["6205283B-BB28-4F9C-AA65-808FE4450542"],"award-info":[{"award-number":["6205283B-BB28-4F9C-AA65-808FE4450542"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310799\/2022-8, 408482\/2022-2"],"award-info":[{"award-number":["310799\/2022-8, 408482\/2022-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88881.507175\/2020-01"],"award-info":[{"award-number":["88881.507175\/2020-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Science and Technology in Dengue and Host-Microorganism Interaction","award":["465425 \/2014-3"],"award-info":[{"award-number":["465425 \/2014-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00011-024-01948-8","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:02:30Z","timestamp":1726660950000},"page":"2009-2022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Angiotensin-(1\u20137) decreases inflammation and lung damage caused by betacoronavirus infection in mice"],"prefix":"10.1007","volume":"73","author":[{"given":"Erick Bryan de Sousa","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Felipe S.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelson H\u00e9ric A.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvaldo S.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Rocha da Silva","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Pedro","family":"Souza-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian de Meira","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso M.","family":"Queiroz-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo C.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson A. S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana P.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro M.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian V.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirl\u00e2ndia P.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni FS, Park J-G, Pino PA, Gonzalez O, Akhter A, Allu\u00e9-Guardia A, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11:6122.","journal-title":"Nat Commun"},{"key":"1948_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41467-023-35928-z","volume":"14","author":"TML Souza","year":"2023","unstructured":"Souza TML, Pinho VD, Setim CF, Sacramento CQ, Marcon R, Fintelman-Rodrigues N, et al. Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation. Nat Commun. 2023;14:199.","journal-title":"Nat Commun"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"e1009195","DOI":"10.1371\/journal.ppat.1009195","volume":"17","author":"CK Yinda","year":"2021","unstructured":"Yinda CK, Port JR, Bushmaker T, Offei Owusu I, Purushotham JN, Avanzato VA, et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog. 2021;17:e1009195.","journal-title":"PLoS Pathog"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/cells10010151","volume":"10","author":"K Janiuk","year":"2021","unstructured":"Janiuk K, Jab\u0142o\u0144ska E, Garley M. Significance of NETs formation in COVID-19. Cells. 2021;10:151.","journal-title":"Cells"},{"key":"1948_CR5","first-page":"8","volume":"15","author":"LF Gonzalez-Mosquera","year":"2022","unstructured":"Gonzalez-Mosquera LF, Gomez-Paz S, Lam E, Cardenas-Maldonado D, Fogel J, Adi V, et al. Hematologic involvement as a predictor of Mortality in COVID-19 patients in a Safety Net Hospital. Kans J Med. 2022;15:8\u201316.","journal-title":"Kans J Med"},{"key":"1948_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762\u20138.","journal-title":"Clin Infect Dis"},{"key":"1948_CR7","doi-asserted-by":"publisher","first-page":"e12967","DOI":"10.1111\/sji.12967","volume":"93","author":"A Jafarzadeh","year":"2021","unstructured":"Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms. Scand J Immunol. 2021;93:e12967.","journal-title":"Scand J Immunol"},{"key":"1948_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33.","journal-title":"Signal Transduct Target Ther"},{"key":"1948_CR9","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jinf.2020.04.012","volume":"81","author":"B Xu","year":"2020","unstructured":"Xu B, Fan C-Y, Wang A-L, Zou Y-L, Yu Y-H, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. 2020;81:e51\u201360.","journal-title":"J Infect"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","volume":"316","author":"RAS Santos","year":"2019","unstructured":"Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316:H958\u201370.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.smim.2022.101601","volume":"59","author":"LP Tavares","year":"2022","unstructured":"Tavares LP, Melo EM, Sousa LP, Teixeira MM. Pro-resolving therapies as potential adjunct treatment for infectious diseases: evidence from studies with annexin A1 and angiotensin-(1\u20137). Semin Immunol. 2022;59:101601.","journal-title":"Semin Immunol"},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bph.16323","volume":"181","author":"VV Costa","year":"2024","unstructured":"Costa VV, Resende F, Melo EM, Teixeira MM. Resolution pharmacology and the treatment of infectious diseases. Br J Pharmacol. 2024;181:917\u201337.","journal-title":"Br J Pharmacol"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"105292","DOI":"10.1016\/j.phrs.2020.105292","volume":"163","author":"EM Melo","year":"2021","unstructured":"Melo EM, Del Sarto J, Vago JP, Tavares LP, Rago F, Gon\u00e7alves APF, et al. Relevance of angiotensin-(1\u20137) and its receptor mas in pneumonia caused by influenza virus and post-influenza pneumococcal infection. Pharmacol Res. 2021;163:105292.","journal-title":"Pharmacol Res"},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1038\/srep07027","volume":"4","author":"P Yang","year":"2014","unstructured":"Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027.","journal-title":"Sci Rep"},{"key":"1948_CR16","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1038\/ncomms4594","volume":"5","author":"Z Zou","year":"2014","unstructured":"Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections. Nat Commun. 2014;5:3594.","journal-title":"Nat Commun"},{"key":"1948_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013e2808.","journal-title":"Cell"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and Regulator of the renin-angiotensin system: celebrating the 20th anniversary of the Discovery of ACE2. Circ Res. 2020;126:1456\u201374.","journal-title":"Circ Res"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u201390.","journal-title":"Intensive Care Med"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"615333","DOI":"10.3389\/fmed.2021.615333","volume":"8","author":"HA Braz-de-Melo","year":"2021","unstructured":"Braz-de-Melo HA, Faria SS, Pasquarelli-do-Nascimento G, Santos I, de O, Kobinger GP, Magalh\u00e3es KG. The Use of the anticoagulant heparin and corticosteroid dexamethasone as prominent treatments for COVID-19. Front Med (Lausanne). 2021;8:615333.","journal-title":"Front Med (Lausanne)"},{"key":"1948_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41423-023-01122-w","volume":"21","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yuan Y, Hu Q, Zhu A, Chen F, Li S, et al. SARS-CoV-2 immunity in animal models. Cell Mol Immunol. 2024;21:119\u201333.","journal-title":"Cell Mol Immunol"},{"key":"1948_CR22","doi-asserted-by":"publisher","first-page":"e0127621","DOI":"10.1128\/jvi.01276-21","volume":"95","author":"ACDSP Andrade","year":"2021","unstructured":"Andrade ACDSP, Campolina-Silva GH, Queiroz-Junior CM, de Oliveira LC, Lacerda L, de Pimenta SB. A Biosafety Level 2 mouse model for studying Betacoronavirus-Induced Acute Lung damage and systemic manifestations. J Virol. 2021;95:e0127621.","journal-title":"J Virol"},{"key":"1948_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/v15102049","volume":"15","author":"Rdas Pereira","year":"2023","unstructured":"Pereira Rdas, Rabelo D, Oliveira RAN, de Porto NF, Andrade SLT, Queiroz-Junior ACDSP. A 5-Lipoxygenase inhibitor, Zileuton, modulates host Immune responses and improves lung function in a model of severe Acute Respiratory Syndrome (SARS) Induced by Betacoronavirus. Viruses. 2023;15:2049.","journal-title":"Viruses"},{"key":"1948_CR24","doi-asserted-by":"crossref","unstructured":"Oliveira VLS, Queiroz-Junior CM, Hoorelbeke D, Santos FR, da Chaves S, de Teixeira I et al. MM,. The glycosaminoglycan-binding chemokine fragment CXCL9(74\u2013103) reduces inflammation and tissue damage in mouse models of coronavirus infection. Front Immunol [Internet]. 2024 [cited 2024 Jun 1];15. Available from.","DOI":"10.3389\/fimmu.2024.1378591"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13054-018-2210-y","volume":"22","author":"H-J Tsai","year":"2018","unstructured":"Tsai H-J, Liao M-H, Shih C-C, Ka S-M, Tsao C-M, Wu C-C. Angiotensin-(1\u20137) attenuates organ injury and mortality in rats with polymicrobial sepsis. Crit Care. 2018;22:269.","journal-title":"Crit Care"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/pharmaceutics13101614","volume":"13","author":"KL Collins","year":"2021","unstructured":"Collins KL, Younis US, Tanyaratsrisakul S, Polt R, Hay M, Mansour HM, et al. Angiotensin-(1\u20137) peptide hormone reduces inflammation and Pathogen Burden during Mycoplasma pneumoniae infection in mice. Pharmaceutics. 2021;13:1614.","journal-title":"Pharmaceutics"},{"key":"1948_CR27","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1111\/bph.15164","volume":"177","author":"LP Sousa","year":"2020","unstructured":"Sousa LP, Pinho V, Teixeira MM. Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: what can the future offer to COVID-19? Br J Pharmacol. 2020;177:3898\u2013904.","journal-title":"Br J Pharmacol"},{"key":"1948_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.120.047297","volume":"141","author":"C Peir\u00f3","year":"2020","unstructured":"Peir\u00f3 C, Moncada S. Substituting Angiotensin-(1\u20137) to prevent lung damage in SARS-CoV-2 infection? Circulation. 2020;141:1665\u20136.","journal-title":"Circulation"},{"key":"1948_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijid.2020.05.002","volume":"96","author":"A Shete","year":"2020","unstructured":"Shete A. Urgent need for evaluating agonists of angiotensin-(1\u20137)\/Mas receptor axis for treating patients with COVID-19. Int J Infect Dis. 2020;96:348\u201351.","journal-title":"Int J Infect Dis"},{"key":"1948_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364\u201374.","journal-title":"Sci China Life Sci"},{"key":"1948_CR31","doi-asserted-by":"publisher","first-page":"847809","DOI":"10.3389\/fcvm.2022.847809","volume":"9","author":"RL Camargo","year":"2022","unstructured":"Camargo RL, Bombassaro B, Monfort-Pires M, Mansour E, Palma AC, Ribeiro LC, et al. Plasma angiotensin II is increased in critical coronavirus Disease 2019. Front Cardiovasc Med. 2022;9:847809.","journal-title":"Front Cardiovasc Med"},{"key":"1948_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/jmv.26479","volume":"93","author":"BM Henry","year":"2021","unstructured":"Henry BM, Benoit JL, Berger BA, Pulvino C, Lavie CJ, Lippi G, et al. Coronavirus disease 2019 is associated with low circulating plasma levels of angiotensin 1 and angiotensin 1,7. J Med Virol. 2021;93:678\u201380.","journal-title":"J Med Virol"},{"key":"1948_CR33","doi-asserted-by":"publisher","first-page":"00114","DOI":"10.1183\/23120541.00114-2021","volume":"7","author":"AL Valle Martins","year":"2021","unstructured":"Valle Martins AL, da Silva FA, Bolais-Ramos L, de Oliveira GC, Ribeiro RC, Pereira DAA, et al. Increased circulating levels of angiotensin-(1\u20137) in severely ill COVID-19 patients. ERJ Open Res. 2021;7:00114\u20132021.","journal-title":"ERJ Open Res"},{"key":"1948_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2023.3546","volume":"329","author":"WH Self","year":"2023","unstructured":"Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, et al. Renin-angiotensin system modulation with synthetic angiotensin (1\u20137) and angiotensin II type 1 receptor-biased ligand in adults with COVID-19: two randomized clinical trials. JAMA. 2023;329:1170\u201382.","journal-title":"JAMA"},{"key":"1948_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2023.10783","volume":"330","author":"RAS Dos Santos","year":"2023","unstructured":"Dos Santos RAS, Taccone FS, Annoni F. Renin-angiotensin system modulation in adults with COVID-19. JAMA. 2023;330:663\u20134.","journal-title":"JAMA"},{"key":"1948_CR36","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.eclinm.2023.102383","volume":"68","author":"SM Lobo","year":"2024","unstructured":"Lobo SM, Plantef\u00e8ve G, Nair G, Joaquim Cavalcante A, Franzin de Moraes N, Nunes E, et al. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2\/3 trial. EClinicalMedicine. 2024;68:102383.","journal-title":"EClinicalMedicine"},{"key":"1948_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/aas.14205","volume":"67","author":"SN Myatra","year":"2023","unstructured":"Myatra SN, Alhazzani W, Belley-Cote E, M\u00f8ller MH, Arabi YM, Chawla R, et al. Awake proning in patients with COVID-19-related hypoxemic acute respiratory failure: a rapid practice guideline. Acta Anaesthesiol Scand. 2023;67:569\u201375.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1948_CR38","doi-asserted-by":"publisher","first-page":"e147819","DOI":"10.1172\/jci.insight.147819","volume":"7","author":"I Zaidan","year":"2022","unstructured":"Zaidan I, Tavares LP, Sugimoto MA, Lima KM, Negreiros-Lima GL, Teixeira LC, et al. Angiotensin-(1\u20137)\/MasR axis promotes migration of monocytes\/macrophages with a regulatory phenotype to perform phagocytosis and efferocytosis. JCI Insight. 2022;7:e147819.","journal-title":"JCI Insight"},{"key":"1948_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jsbmb.2018.08.007","volume":"185","author":"K Itcho","year":"2019","unstructured":"Itcho K, Oki K, Kobuke K, Ohno H, Yoneda M, Hattori N. Angiotensin 1\u20137 suppresses angiotensin II mediated aldosterone production via JAK\/STAT signaling inhibition. J Steroid Biochem Mol Biol. 2019;185:137\u201341.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1948_CR40","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3390\/v13122379","volume":"13","author":"IJ Ezeonwumelu","year":"2021","unstructured":"Ezeonwumelu IJ, Garcia-Vidal E, Ballana E. JAK-STAT pathway: a Novel Target to tackle viral infections. Viruses. 2021;13:2379.","journal-title":"Viruses"},{"key":"1948_CR41","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30\u20131.","journal-title":"Lancet"},{"key":"1948_CR42","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/jcm10061200","volume":"10","author":"SN Heyman","year":"2021","unstructured":"Heyman SN, Walther T, Abassi Z. Angiotensin-(1\u20137)-A potential remedy for AKI: insights derived from the COVID-19 pandemic. J Clin Med. 2021;10:1200.","journal-title":"J Clin Med"},{"key":"1948_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13054-022-04034-9","volume":"26","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang Y, Qin X, Jiang X, Zhang J, Mao L, et al. Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein. Crit Care. 2022;26:171.","journal-title":"Crit Care"},{"key":"1948_CR44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1948_CR45","doi-asserted-by":"publisher","first-page":"110858","DOI":"10.1016\/j.intimp.2023.110858","volume":"124","author":"D Felkle","year":"2023","unstructured":"Felkle D, Zi\u0119ba K, Kaleta K, Czaja J, Zyzdorf A, Soboci\u0144ska W, et al. Overreactive macrophages in SARS-CoV-2 infection: the effects of ACEI. Int Immunopharmacol. 2023;124:110858.","journal-title":"Int Immunopharmacol"},{"key":"1948_CR46","doi-asserted-by":"crossref","unstructured":"Magalhaes GS, Gregorio JF, Beltrami VA, Felix FB, Oliveira-Campos L, Bonilha CS et al. A single dose of angiotensin-(1\u20137) resolves eosinophilic inflammation and protects the lungs from a secondary inflammatory challenge. Inflamm Res [Internet]. 2024 [cited 2024 May 11];.","DOI":"10.1007\/s00011-024-01880-x"},{"key":"1948_CR47","doi-asserted-by":"publisher","first-page":"2401081","DOI":"10.1155\/2019\/2401081","volume":"2019","author":"M de Carvalho Santuchi","year":"2019","unstructured":"de Carvalho Santuchi M, Dutra MF, Vago JP, Lima KM, Galv\u00e3o I, de Souza-Neto FP, et al. Angiotensin-(1\u20137) and Alamandine promote anti-inflammatory response in Macrophages in Vitro and in vivo. Mediators Inflamm. 2019;2019:2401081.","journal-title":"Mediators Inflamm"},{"key":"1948_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jmii.2023.09.003","volume":"56","author":"Y-L Shen","year":"2023","unstructured":"Shen Y-L, Hsieh Y-A, Hu P-W, Lo P-C, Hsiao Y-H, Ko H-K, et al. Angiotensin-(1\u20137) attenuates SARS-CoV2 spike protein-induced interleukin-6 and interleukin-8 production in alveolar epithelial cells through activation of Mas receptor. J Microbiol Immunol Infect. 2023;56:1147\u201357.","journal-title":"J Microbiol Immunol Infect"},{"key":"1948_CR49","doi-asserted-by":"publisher","first-page":"171042","DOI":"10.1016\/j.peptides.2023.171042","volume":"167","author":"P Passaglia","year":"2023","unstructured":"Passaglia P, Silva HB, de Jesus AA, Filho MAM, Trajano IP, Batalh\u00e3o ME, et al. Angiotensin-(1\u2009\u2013\u20097) improves tail skin heat loss and increases the survival of rats with polymicrobial sepsis. Peptides. 2023;167:171042.","journal-title":"Peptides"},{"key":"1948_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13054-023-04396-8","volume":"27","author":"B Garcia","year":"2023","unstructured":"Garcia B, Su F, Manicone F, Dewachter L, Favory R, Khaldi A, et al. Angiotensin 1\u20137 in an experimental septic shock model. Crit Care. 2023;27:106.","journal-title":"Crit Care"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"205873842110485","DOI":"10.1177\/20587384211048567","volume":"35","author":"P Zhang","year":"2021","unstructured":"Zhang P, Du W, Yang T, Zhao L, Xiong R, Li Y, et al. Lymphocyte subsets as a predictor of severity and prognosis in COVID-19 patients. Int J Immunopathol Pharmacol. 2021;35:20587384211048567.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41577-020-00470-2","volume":"21","author":"R Alon","year":"2021","unstructured":"Alon R, Sportiello M, Kozlovski S, Kumar A, Reilly EC, Zarbock A, et al. Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. Nat Rev Immunol. 2021;21:49\u201364.","journal-title":"Nat Rev Immunol"},{"key":"1948_CR53","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.3324\/haematol.2018.193771","volume":"103","author":"K Gaffney","year":"2018","unstructured":"Gaffney K, Weinberg M, Soto M, Louie S, Rodgers K. Development of angiotensin II (1\u20137) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression. Haematologica. 2018;103:e567\u201370.","journal-title":"Haematologica"},{"key":"1948_CR54","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00280-013-2312-9","volume":"72","author":"KE Rodgers","year":"2013","unstructured":"Rodgers KE, Espinoza TB, Roda N, Meeks CJ, diZerega GS. Angiotensin-(1\u20137) synergizes with colony-stimulating factors in hematopoietic recovery. Cancer Chemother Pharmacol. 2013;72:1235\u201345.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fendo.2013.00157","volume":"4","author":"KE Rodgers","year":"2013","unstructured":"Rodgers KE, diZerega GS. Contribution of the local RAS to hematopoietic function: a Novel Therapeutic Target. Front Endocrinol (Lausanne). 2013;4:157.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1948_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s13054-023-04739-5","volume":"27","author":"B Garcia","year":"2023","unstructured":"Garcia B, Zarbock A, Bellomo R, Legrand M. The alternative renin\u2013angiotensin system in critically ill patients: pathophysiology and therapeutic implications. Crit Care. 2023;27:453.","journal-title":"Crit Care"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-024-01948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-024-01948-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-024-01948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:19:30Z","timestamp":1730891970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-024-01948-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s00011-024-01948-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4529565\/v1","asserted-by":"object"}]},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}